Regenerative Medicine Company Embody Secures $3.6M Funding to Advance Collagen Microfiber Implant Tapestry

VCBeat (WeChat ID: vcbeat) has learned that regenerative medicine company Embody recently completed a $3.6 million financing round to advance the commercialization of its innovative collagen microfibril implant, Tapestry.

The funding for this round was provided by Cultivate(MD) Capital Fund II, LP, managed by Genesis Innovation Group. On August 29, 2018, 757 Angels and CIT GAP Funds previously invested $1.5 million in Embody. Upon the completion of this financing round, Embody’s total fundraising will reach $5.1 million.

Embody, Inc., founded in 2015, is a regenerative medicine company based in Virginia, USA. The company focuses on the development and commercialization of implantable medical devices, leveraging innovative biomaterial design and biofabrication technologies to improve outcomes in soft tissue surgical procedures.

Tapestry’s design is based on research into accelerated collagen recellularization for Achilles tendon and ligament repair, addressing over 750,000 surgical cases annually in the United States. Embody is overcoming the previous limitations of collagen in drug delivery and wound healing applications through innovative biomaterial design, improved electrospinning, and microfluidics.

Matt Ahearn, Vice President of Finance and Operations at Genesis Innovation Group, stated, “We were deeply impressed by the innovative spirit of Embody’s CEO, Jeff Conroy, and his team. We are fully confident in driving the commercialization of Tapestry.”

Jeff Conroy, CEO of Embody, stated, “Genesis Innovation Group’s years of experience in the plastic surgery industry can provide valuable insights for Embody’s product development. Genesis Innovation Group is not only our investor but also our strategic partner.”

Genesis Innovation Group is a technology-driven company based in Montana, USA, specializing in the field of plastic surgery.

Cultivate(MD) Capital Fund is a healthcare venture capital fund dedicated to bringing emerging healthcare innovations to market, with a focus on investing in early-stage healthcare companies.

757 Angels, established in 2015, is a business leader angel investment network based in Virginia, USA, providing selected startups and early-stage companies with investment capital, strategic advice, and mentorship to help them achieve market leadership.

CIT GAP Funds was established in 2003, with its headquarters located in Virginia, USA, and specializes in investing in seed-stage technology companies.

(Compiled by Yang Shiying)